An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

High Lipoprotein (a) is a genetic condition that increases the risk of early heart attacks and strokes. It is one of the most common genetic risk factors for cardiovascular disease, yet it remains ...

Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points compared ...

I have had cholesterol tests for the past 30 years with HDL readings that had a low of 68 mg/dL and a high of 117 mg/dL.

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Low-density lipoprotein (LDL) cholesterol, or “bad” cholesterol, collects in the walls of the blood vessels, causing them to narrow. High-density lipoprotein (HDL), or “good” cholesterol ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...